Wird diese Nachricht nicht richtig dargestellt, klicken Sie bitte hier.


What´s up at IZB 

Dear Mister/Miss Titel ,

Following an 8 million euro grant from the German government, Eisbach Bio has now also received a 6.7 million euro grant from the Bavarian government to develop a drug against COVID-19. We are extremely proud that a drug from Bavaria is expected to be on the market in 2023. And SciRhom also announced today an increase in seed funding to 16 million euros.

And who would have thought that the vegan AMSilk silk would soon be used in aircraft construction or as an ecological pesticide? We interviewed Ulrich Scherbel, CEO of AMSilk, about the current business development.

Concerning integration of eHealth in oncology therapy management and new RNA transport systems we were able to record the lectures of Prof. Nadia Harbeck and Prof. Oliva Merkel for you in their entirety during the ZBrunch.

Enjoy reading the new newsletter!

With snowy greetings from the IZB

Your Dr. Peter Hanns Zobel
Managing Director IZB
SciRhom:
Seed funding increased to 16 million euros

With this, the start-up brings its drug candidates for rheumatoid arthritis and inflammatory bowel disease into the clinic
More info...

 Dr. Jens Ruhe, Geschäftsführer SciRhom
Silikon-Brustimplantate mit den Seiden-Biopolymeren von AMSilk AMSilk-Video:
Vegan silk for industrial production
Interview with Ulrich Scherbel, Managing Director AMSilk GmbH
Learn more ...

Eisbach Bio:
6.7 million euros in funding

Bavarian state government supports the development of a COVID-19 drug
Learn more ...

 Die richtigen Tools treiben die Stammzell-Forschung voran
„Karamell-Rezeptor“ gefunden

Leibniz Institute:
Caramel receptor found

Better understanding of the molecular coding of food flavors
Learn more ...
PELOBiotech: 
Stem cell research
with new tools

PELOBiotech launches a revolutionary, truly chemically defined medium.

Learn more ...
 Die richtigen Tools treiben die Stammzell-Forschung voran
„Karamell-Rezeptor“ gefunden

Speaker: 
Prof. Nadia Harbeck and Dr. Jens Ruhe

Learn more...
Exosome Diagnostics: 

From idea to exit

Mikkel Noerholm built up the diagnostic company at the IZB and accompanied its sale to Bio-Techne
Learn more...
 Mikkel Noerholm PhD Vice President Exosome Diagnostics
„Karamell-Rezeptor“ gefunden

Modag:
Drug candidate for neurodegenerative diseases

Cooperation with Teva Pharmaceuticals Ltd in Tel Aviv 
Learn more...
Sterna Biologicals: 
Innovative Phase II-A study design in Asthma
Antisense treatment is combined with digital therapy 
More info ...
 Die richtigen Tools treiben die Stammzell-Forschung voran
CAMPUS
„Karamell-Rezeptor“ gefunden

MPI Neurobiologie: 
Abstract learning

New study: in which brain region is acquired knowledge stored?

More info ...
LMU Pharmazie: 
Prof. Olivia Merkel
Development of new RNA Transport systems
More info ...
 Die richtigen Tools treiben die Stammzell-Forschung voran
Prof. Nadia Harbeck, Leiterin Brustzentrum der LMU

Breast center of the LMU 
Prof. Dr. Nadia Harbeck
Integration of eHealth in oncology therapy management
More info ...
IZB INTERN
IZB Anniverary
25 years in the service of IZB

Dr. Peter Hanns Zobel, Managing Director of the IZB, celebrated on November, 2 2021 his
25-anniversary at the IZB. 
More info...
 Dr. Peter Hanns Zobel, GF IZB



Contact

Susanne Simon
Head of Public Relations
Tel.: 089/55 279 48-17
E-Mail: izb@izb-online.de          

IZB Martinsried:

Fördergesellschaft IZB mbH
Am Klopferspitz 19
82152 Planegg/Martinsried

IZB Weihenstephan:

Fördergesellschaft IZB mbH
Lise-Meitner-Strae 30
85354 Freising/Weihenstephan


Wenn Sie diese E-Mail (an: unknown@noemail.com) nicht mehr empfangen möchten, können Sie diese hier kostenlos abbestellen.

Fördergesellschaft IZB mbH
Dr. Peter Hanns Zobel
Am Klopferspitz, 19
82152 Planegg
Deutschland

+4989552794817
info@izb-online.de